Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Gianluca Ianiro, Franco Scaldaferri, Eleonora Gaetani, Antonio Gasbarrini, Lucrezia Laterza, Iolanda Scoleri, Rosario Landi, Mariachiara Campanale

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)

Abstract

Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.
Lingua originaleEnglish
pagine (da-a)607-615
Numero di pagine9
RivistaEXPERT OPINION ON PHARMACOTHERAPY
Volume16
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Animals
  • Anti-Bacterial Agents
  • Diarrhea
  • Drug Interactions
  • Drug Resistance, Bacterial
  • Humans
  • Irritable Bowel Syndrome
  • Rifamycins
  • antibiotics
  • gut microbiota
  • irritable bowel syndrome
  • pharmacokinetic
  • rifaximin

Fingerprint

Entra nei temi di ricerca di 'Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome'. Insieme formano una fingerprint unica.

Cita questo